- Home
- AMWD vs GHRS Comparison
AMWD vs GHRS Comparison
Compare AMWD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWD
- GHRS
- Stock Information
- Founded
- AMWD 1980
- GHRS 2018
- Country
- AMWD United States
- GHRS Ireland
- Employees
- AMWD N/A
- GHRS N/A
- Industry
- AMWD Forest Products
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AMWD Basic Materials
- GHRS Health Care
- Exchange
- AMWD Nasdaq
- GHRS Nasdaq
- Market Cap
- AMWD 907.4M
- GHRS 753.0M
- IPO Year
- AMWD N/A
- GHRS 2021
- Fundamental
- Price
- AMWD $67.18
- GHRS $13.08
- Analyst Decision
- AMWD Buy
- GHRS Strong Buy
- Analyst Count
- AMWD 4
- GHRS 8
- Target Price
- AMWD $83.33
- GHRS $30.63
- AVG Volume (30 Days)
- AMWD 267.3K
- GHRS 254.5K
- Earning Date
- AMWD 08-26-2025
- GHRS 08-07-2025
- Dividend Yield
- AMWD N/A
- GHRS N/A
- EPS Growth
- AMWD N/A
- GHRS N/A
- EPS
- AMWD 6.50
- GHRS N/A
- Revenue
- AMWD $1,709,585,000.00
- GHRS N/A
- Revenue This Year
- AMWD N/A
- GHRS N/A
- Revenue Next Year
- AMWD $4.03
- GHRS N/A
- P/E Ratio
- AMWD $10.30
- GHRS N/A
- Revenue Growth
- AMWD N/A
- GHRS N/A
- 52 Week Low
- AMWD $50.00
- GHRS $6.00
- 52 Week High
- AMWD $104.28
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AMWD 65.55
- GHRS 47.54
- Support Level
- AMWD $60.92
- GHRS $11.32
- Resistance Level
- AMWD $65.97
- GHRS $13.15
- Average True Range (ATR)
- AMWD 3.08
- GHRS 0.73
- MACD
- AMWD 0.40
- GHRS 0.05
- Stochastic Oscillator
- AMWD 97.46
- GHRS 77.19
About AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.